📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
4 articles
AVG GRADE
NEUTRAL
score: 0.38
SENTIMENT
NEUTRAL
TOTAL VIEWS
18
TENX Latest News & AI Sentiment Analysis
4 articles · Grade: NEUTRAL · Real-time AI-graded coverage
RECENT COVERAGE · 6 ARTICLES
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients - Slideshow (NASDAQ:TENX) 2026-08-11
Tenax Therapeutics (TENX) released a slide deck presentation discussing Phase III LEVEL trial outcomes for its oral levosimendan...
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript
TENX released a transcript discussing Phase III LEVEL trial results for oral levosimendan in heart failure with preserved ejection...
Tenax Therapeutics: Double Or Nothing (NASDAQ:TENX)
Tenax Therapeutics (TENX) faces a pivotal moment with Phase 3 LEVEL trial data on its oral levosimendan candidate. The binary nature of...
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Tenax Therapeutics (TENX) disclosed Q2 2026 financial results alongside a near-term clinical inflection point, with Phase 3 LEVEL trial...
Tenax Therapeutics: 'Hold' TNX-103 Data August 2026 - But With Caution Ahead (NASDAQ:TENX)
Tenax Therapeutics (TENX) has been downgraded to Hold status as the market awaits Phase 3 trial results for TNX-103, a heart failure...
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TENX announced inducement option grants to three newly hired employees in accounting, clinical operations, and CMC/product development...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice